Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
An easy reference to world market indices names, with notes on regional coverage and how to recognize key benchmarks in discussions.
28,329 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Rising tensions over the Strait of Hormuz have sparked volatile moves in oil and equity markets as U.S. intelligence ...
A veteran trader explains why dividend-heavy healthcare equities remain a bedrock in 2026 markets, drawing on two dec...
Novo Nordisk isn’t in the spotlight, but its steady cash flow and strong pipeline could unlock long-term gains. This ...
In 2025, rare earths drew intense attention as prices and equities raced higher. The rally cooled quickly, leaving in...
A wave of money is moving beyond U.S. markets. International stock funds are pulling in large inflows, signaling a sh...
Policymakers are weighing tax shifts that could touch luxury spending by the ultra-wealthy. Investors watch designer ...
XRP sits around $1.40 as institutions quietly expand tokenized-asset settlements on public rails, even as on-chain ac...
At this year’s Fortune COO Summit, a simple question exposed a quiet truth: many COOs hesitate to voice CEO ambitions...
As volatility rises and bond yields shift, retirees seek reliable income. Covered call ETFs like XYLD and RYLD offer ...
When a chief operating officer sells stock, investors take notice. This article breaks down the implications, explain...
BlackRock kicked off 2026 with record ETF inflows and a quarterly earnings beat, fueling optimism across markets. The...